JP2013520519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520519A5 JP2013520519A5 JP2012555160A JP2012555160A JP2013520519A5 JP 2013520519 A5 JP2013520519 A5 JP 2013520519A5 JP 2012555160 A JP2012555160 A JP 2012555160A JP 2012555160 A JP2012555160 A JP 2012555160A JP 2013520519 A5 JP2013520519 A5 JP 2013520519A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- item
- process according
- generating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 53
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000029936 alkylation Effects 0.000 claims description 5
- 238000005804 alkylation reaction Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000032050 esterification Effects 0.000 claims description 5
- 238000005886 esterification reaction Methods 0.000 claims description 5
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 0 CC(C1)C=CC(*)=C1[N+]([O-])=O Chemical compound CC(C1)C=CC(*)=C1[N+]([O-])=O 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- OEKATORRSPXJHE-UHFFFAOYSA-N 2-acetylcyclohexan-1-one Chemical compound CC(=O)C1CCCCC1=O OEKATORRSPXJHE-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical group IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30779610P | 2010-02-24 | 2010-02-24 | |
| US61/307,796 | 2010-02-24 | ||
| PCT/US2011/026135 WO2011106570A1 (en) | 2010-02-24 | 2011-02-24 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520519A JP2013520519A (ja) | 2013-06-06 |
| JP2013520519A5 true JP2013520519A5 (enExample) | 2014-01-30 |
| JP5718372B2 JP5718372B2 (ja) | 2015-05-13 |
Family
ID=44507217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555160A Active JP5718372B2 (ja) | 2010-02-24 | 2011-02-24 | ジアリールチオヒダントイン化合物およびジアリールヒダントイン化合物を合成するためのプロセス |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9174943B2 (enExample) |
| EP (2) | EP2538785B1 (enExample) |
| JP (1) | JP5718372B2 (enExample) |
| KR (1) | KR101514659B1 (enExample) |
| CN (1) | CN103108549B (enExample) |
| BR (1) | BR112012021406B1 (enExample) |
| CA (1) | CA2790924C (enExample) |
| CY (2) | CY1120207T1 (enExample) |
| DK (2) | DK3329775T3 (enExample) |
| ES (2) | ES2671343T3 (enExample) |
| HU (2) | HUE038637T2 (enExample) |
| MX (1) | MX2012009782A (enExample) |
| PL (2) | PL2538785T3 (enExample) |
| PT (2) | PT3329775T (enExample) |
| RU (1) | RU2554081C2 (enExample) |
| SI (2) | SI3329775T1 (enExample) |
| WO (1) | WO2011106570A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP2220050A2 (en) | 2007-10-26 | 2010-08-25 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor modulators |
| AU2011218173C1 (en) * | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2012225038B2 (en) | 2011-03-10 | 2016-03-10 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
| PL3725778T3 (pl) * | 2012-09-11 | 2021-12-20 | Medivation Prostate Therapeutics Llc | Preparaty enzalutamidu |
| AU2013316754A1 (en) * | 2012-09-11 | 2015-04-30 | Dr. Reddy's Laboratories Limited | Enzalutamide polymorphic forms and its preparation |
| IL312316A (en) | 2012-09-26 | 2024-06-01 | Aragon Pharmaceuticals Inc | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases |
| EP2911666B1 (en) | 2012-10-26 | 2022-08-24 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| RU2520134C1 (ru) * | 2013-02-27 | 2014-06-20 | Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") | Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| RU2016110546A (ru) * | 2013-09-19 | 2017-10-24 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированная лекарственная терапия |
| CN106543085A (zh) * | 2013-10-14 | 2017-03-29 | 杭州普晒医药科技有限公司 | 恩杂鲁胺的固态形式及其制备方法和用途 |
| WO2015063720A1 (en) | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| US20160318875A1 (en) | 2013-12-16 | 2016-11-03 | Sun Pharmaceutical Industries Limited | Processes and intermediates for the preparation of enzalutamide |
| CN104803918B (zh) * | 2014-01-26 | 2017-11-10 | 上海医药工业研究院 | 恩杂鲁胺的制备方法 |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| US9611225B2 (en) * | 2014-01-27 | 2017-04-04 | Cadila Healthcare Limited | Process for preparation of androgen receptor antagonist |
| CN104844521B (zh) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | 抗前列腺癌药物恩杂鲁胺的合成方法 |
| CN104844520B (zh) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| WO2015121768A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| CZ2014232A3 (cs) | 2014-04-07 | 2015-10-14 | Zentiva, K.S. | Způsob výroby enzalutamidu |
| CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
| CN103980141A (zh) * | 2014-04-25 | 2014-08-13 | 山东大学 | 恩泽特鲁的合成方法 |
| CN104016924B (zh) * | 2014-06-16 | 2016-04-13 | 上海鼎雅药物化学科技有限公司 | 一种“一锅法”合成恩杂鲁胺的方法 |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| WO2016005875A1 (en) * | 2014-07-11 | 2016-01-14 | Shilpa Medicare Limited | An improved process for the preparation of enzalutamide |
| CN105461633A (zh) * | 2014-07-31 | 2016-04-06 | 江苏豪森药业集团有限公司 | 恩杂鲁胺的制备方法 |
| CN105367441B (zh) * | 2014-08-18 | 2018-11-06 | 上海医药工业研究院 | 用于合成恩杂鲁胺的新化合物 |
| CN105461634A (zh) * | 2014-08-19 | 2016-04-06 | 江苏豪森药业集团有限公司 | 恩杂鲁胺的制备方法 |
| WO2016051423A2 (en) * | 2014-10-01 | 2016-04-07 | Laurus Labs Private Limited | An improved process for the preparation of enzalutamide |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| PT3233803T (pt) * | 2014-12-19 | 2019-05-20 | Aragon Pharmaceuticals Inc | Processo para a preparação de um composto diariltioidantoína |
| ITUB20151311A1 (it) * | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| ITUB20151204A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| ITUB20151256A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Processo industriale per la preparazione di enzalutamide |
| EP3305770B1 (en) | 2015-05-29 | 2023-03-29 | Astellas Pharma Inc. | Process for producing enzalutamide crystal form |
| TWI613194B (zh) * | 2015-06-10 | 2018-02-01 | 台灣神隆股份有限公司 | 用於製備恩雜魯胺的新穎方法 |
| CN105330560A (zh) * | 2015-10-13 | 2016-02-17 | 福格森（武汉）生物科技股份有限公司 | 一种恩杂鲁胺中间体的制备方法 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| PT3616696T (pt) | 2017-04-28 | 2025-04-03 | Astellas Pharma Inc | Composição farmacêutica administrável oralmente contendo enzalutamida |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
| HUE064356T2 (hu) * | 2017-11-28 | 2024-03-28 | Aarti Pharmalabs Ltd | Eljárás enzalutamid elõállítására új intermedier felhasználásával |
| CN108047200A (zh) * | 2017-12-05 | 2018-05-18 | 上海丰瑞医药科技有限公司 | 一种二芳基乙内酰硫脲类化合物的制备方法及其中间体 |
| CN109988077A (zh) * | 2017-12-29 | 2019-07-09 | 上海法默生物科技有限公司 | 一种阿帕鲁胺的合成方法及中间体 |
| CN110872258B (zh) * | 2018-09-04 | 2021-05-25 | 北京凯莱天成医药科技有限公司 | 一种前列腺癌药物恩杂鲁胺的制备工艺 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN109503416A (zh) * | 2018-12-24 | 2019-03-22 | 常州智超化学有限公司 | 一种恩杂鲁胺中间体合成方法 |
| CN112047888B (zh) * | 2019-06-05 | 2024-08-02 | 安礼特（上海）医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| CN111320552B (zh) * | 2020-02-28 | 2023-10-27 | 江西科睿药业有限公司 | 一种恩扎卢胺中间体的制备方法 |
| EP4023649A1 (en) | 2020-12-30 | 2022-07-06 | Industrial Technology Research Institute | Androgen receptor binding bifunctional molecules |
| WO2022206742A1 (zh) * | 2021-03-30 | 2022-10-06 | 苏州开拓药业股份有限公司 | 一种一步法合成乙内酰硫脲衍生物的方法 |
| EP4112603A1 (en) | 2021-06-29 | 2023-01-04 | Química Sintética, S.A. | Processes for the preparation of non-steroidal antiandrogens |
| CN115572264B (zh) * | 2021-07-06 | 2025-12-05 | 山东新时代药业有限公司 | 一种恩杂鲁胺的制备方法 |
| CN113698310B (zh) * | 2021-08-20 | 2023-03-17 | 江西金丰药业有限公司 | 一种恩杂鲁胺双酯中间体的制备方法 |
| CN114591246A (zh) * | 2022-03-25 | 2022-06-07 | 重庆华邦制药有限公司 | 一种恩扎卢胺的纯化方法 |
| CN114907439B (zh) * | 2022-06-29 | 2023-07-21 | 云南中医药大学 | 一种抗癌化合物及其制药用途 |
| CN115181043B (zh) * | 2022-07-27 | 2024-05-07 | 爱斯特（成都）生物制药股份有限公司 | 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法 |
| CN115611765A (zh) * | 2022-09-30 | 2023-01-17 | 重庆华邦胜凯制药有限公司 | 一种恩扎卢胺中间体的制备方法 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN115724759B (zh) * | 2022-11-23 | 2024-06-25 | 爱斯特（成都）生物制药股份有限公司 | 一种恩扎卢胺中间体的制备方法 |
| CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
| CN118496163B (zh) * | 2024-05-08 | 2025-02-25 | 奥锐特药业股份有限公司 | 一种恩扎卢胺及其中间体的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2884448A (en) * | 1956-07-02 | 1959-04-28 | Gen Aniline & Film Corp | Hydrolysis of n-substituted amides |
| DE1906492B2 (de) * | 1969-02-10 | 1980-07-31 | Bayer Ag, 5090 Leverkusen | Carbonsäure-Derivate enthaltende Hydantoine und Polyhydantoine |
| US4424396A (en) * | 1982-07-21 | 1984-01-03 | Occidental Chemical Corporation | Process for the preparation substituted anilino acids |
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5235093A (en) * | 1992-01-27 | 1993-08-10 | Monsanto Company | Process for preparing carboxylic amide ester |
| FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
| RU2206326C2 (ru) | 2001-04-10 | 2003-06-20 | Асафов Александр Виленович | Применение натрия нуклеоспермата для лечения вич-инфекции и способ лечения |
| EP1790640A4 (en) | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| KR101579701B1 (ko) * | 2005-05-13 | 2015-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| DK2656842T3 (en) | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| EP3020706A1 (en) * | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
| TW200846338A (en) * | 2007-02-01 | 2008-12-01 | Chugai Pharmaceutical Co Ltd | Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2220050A2 (en) | 2007-10-26 | 2010-08-25 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor modulators |
| CN101896469A (zh) * | 2007-12-20 | 2010-11-24 | 霍夫曼-拉罗奇有限公司 | 作为mek激酶抑制剂的取代的乙内酰脲类化合物 |
| EP2400847B1 (en) * | 2009-02-24 | 2014-12-17 | Medivation Prostate Therapeutics, Inc. | Specific diarylthiohydantoin compounds |
| WO2010118354A1 (en) * | 2009-04-09 | 2010-10-14 | Medivation Prostate Therapeutics, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
-
2011
- 2011-02-24 JP JP2012555160A patent/JP5718372B2/ja active Active
- 2011-02-24 DK DK18153287.0T patent/DK3329775T3/da active
- 2011-02-24 HU HUE11748095A patent/HUE038637T2/hu unknown
- 2011-02-24 KR KR1020127024687A patent/KR101514659B1/ko active Active
- 2011-02-24 ES ES11748095.4T patent/ES2671343T3/es active Active
- 2011-02-24 PT PT181532870T patent/PT3329775T/pt unknown
- 2011-02-24 SI SI201131988T patent/SI3329775T1/sl unknown
- 2011-02-24 PT PT117480954T patent/PT2538785T/pt unknown
- 2011-02-24 ES ES18153287T patent/ES2880354T3/es active Active
- 2011-02-24 CA CA2790924A patent/CA2790924C/en active Active
- 2011-02-24 EP EP11748095.4A patent/EP2538785B1/en active Active
- 2011-02-24 PL PL11748095T patent/PL2538785T3/pl unknown
- 2011-02-24 DK DK11748095.4T patent/DK2538785T3/en active
- 2011-02-24 BR BR112012021406-3A patent/BR112012021406B1/pt active IP Right Grant
- 2011-02-24 EP EP18153287.0A patent/EP3329775B1/en active Active
- 2011-02-24 HU HUE18153287A patent/HUE055051T2/hu unknown
- 2011-02-24 PL PL18153287T patent/PL3329775T3/pl unknown
- 2011-02-24 WO PCT/US2011/026135 patent/WO2011106570A1/en not_active Ceased
- 2011-02-24 CN CN201180020668.7A patent/CN103108549B/zh active Active
- 2011-02-24 SI SI201131468T patent/SI2538785T1/en unknown
- 2011-02-24 RU RU2012140454/04A patent/RU2554081C2/ru active
- 2011-02-24 MX MX2012009782A patent/MX2012009782A/es active IP Right Grant
-
2013
- 2013-03-05 US US13/785,504 patent/US9174943B2/en active Active
-
2018
- 2018-05-15 CY CY20181100501T patent/CY1120207T1/el unknown
-
2021
- 2021-07-20 CY CY20211100657T patent/CY1124334T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520519A5 (enExample) | ||
| TWI720966B (zh) | 二烷基胺基矽烷的製造方法 | |
| JP5449181B2 (ja) | ２−アミノ−５−シアノ安息香酸誘導体を調製するための方法 | |
| JP2013512988A5 (enExample) | ||
| JP2012515142A5 (enExample) | ||
| CN102351894A (zh) | 一种甲基苯基二烷氧基硅烷的制备方法 | |
| JP2013508368A5 (enExample) | ||
| JP6685386B2 (ja) | （メタ）アクリレート基を有する有機ケイ素化合物およびその製造方法 | |
| JP2017043560A (ja) | 含窒素有機ケイ素化合物および樹脂組成物 | |
| CN102617434A (zh) | 一锅法制备维达列汀 | |
| JP2009502814A (ja) | Ｎ置換イソチアゾリノン誘導体の製造 | |
| JP5231372B2 (ja) | アミンボランの合成 | |
| JP5374895B2 (ja) | 光学活性フルオロアミン類の製造方法 | |
| JP2018009100A5 (enExample) | ||
| JP5420751B2 (ja) | １，３−ビス（アミノアルキル）ジシロキサンの合成方法 | |
| US8487124B2 (en) | Cyclic aza-sila compounds | |
| ES2576189T3 (es) | Método para la preparación de di-organo-dialcoxisilanos | |
| JP5453885B2 (ja) | Ｎ−モノメチル−３，５−ジブロモアニリン化合物およびその製造法 | |
| JP6419979B2 (ja) | シアノアルキルフルオロシランの製造方法 | |
| JP5520816B2 (ja) | アミンおよびアミンオキシドで開始するアルキルホスフィン酸の合成方法 | |
| NZ597620A (en) | A process for the synthesis of naratriptan | |
| KR102376869B1 (ko) | 요오드 함유 규소 화합물의 제조 방법 | |
| JP2013001653A (ja) | フルオロ硫酸エノールエステル類の製造方法 | |
| JP2017514845A5 (enExample) | ||
| JP2008512451A (ja) | ホスフィン酸アルキルの製造方法 |